Vernalis and Servier Achieve Research Milestone in Drug Discovery Collaboration

Vernalis plc and Servier, Suresnes, France, today announce they have achieved a research milestone in one of their oncology drug discovery collaborations. As a result, Vernalis will receive a payment of €0.5m from Servier in recognition of reaching this stage in the programme.
This collaboration between Vernalis and Servier utilises Vernalis’ proprietary fragment and structure-based drug discovery platform on undisclosed oncology targets. Vernalis will receive fees and a share in the future success of the product in the form of milestones and royalties on sales. Financial terms of the collaboration have not been disclosed.

Ian Garland, CEO of Vernalis commented: “This achievement is a further endorsement of our proprietary fragment and structure-based drug discovery platforms and the strength of our collaborative partnership with Servier. We look forward to further success with these collaborations”.
Bernard Marchand, PhD, General Manager of Servier Discovery Research, added: “We are very pleased with the progress of this collaboration showing once again the added value of integrated structural biology on a challenging oncology target”.

Science Park Cambridge

Pictured: Ian Garland, CEO Vernalis